Earnings call transcript: PYC Therapeutics posts Q3 2026 EPS beat as trial data lifts outlook

PYC Therapeutics announced earnings for Q3 2026, posting an EPS of -$0.0233, which greatly surpassed the expected loss of -$7.60. The company's revenue reached $28.64 million, though no comparison revenue was provided. The management emphasized the company's progress in clinical development rather than financial performance during the Q3 investor webinar.

PYC Therapeutics is entering a critical period of clinical development, having reported an adjusted quarterly loss that was significantly smaller than expected. The company has outlined a series of human data readouts through 2027, marking its transition from an early-stage research company to a late-stage clinical development group.

The lead program, PYC-003 for autosomal dominant polycystic kidney disease (ADPKD), is moving through Phase I-B with 13 of 24 patients enrolled. Management highlighted the company's balance sheet strength, stating that it has enough capital to fund development through multiple late-stage programs. The company is preparing for potential U.S. listing steps and is entering a key window for human safety and efficacy data.

Among the other programs, PYC-001 for autosomal dominant optic atrophy and PYC-002 for Phelan-McDermid syndrome showed progress. Management also discussed the possibility of expanding the kidney program's patient cohort and extending the data set to provide a 24-month period. The company's approach to the kidney program is considered more specific, with a clean safety profile and lower doses compared to some rivals.

PYC Therapeutics' stock rose 2.65% in after-hours trading to $2.32 after the earnings call, indicating a positive market response to the company's clinical update and balance sheet comments. The stock later traded at $2.565, close to the top of its 52-week range of $0.848 to $2.62. The positive price action suggests investors are encouraged by the company's clinical milestones and financial position.